Breast Cancer PDX
StemMed has exclusive license to a large collection of quality-controlled, low passage, human breast cancer PDX representing all clinically-defined subtypes for use in preclinical drug testing. PDX are maintained exclusively in the epithelium-free mammary fat pad of immunodeficient mice. These models have been characterized extensively and serve as a renewable resource for preclinical studies of tumor biology, drug treatment response, and metastasis.
Currently, we have 40 PDX models representing 32 unique patients.
These include:
- “Triple-negative” (ER-PR-HER2-) PDX | 24
- ER+PR+ PDX | 2
- ER+ PDX | 2
- “Triple-positive” (ER+PR+HER2+) PDX | 1
- HER2+ PDX | 3
Key features of breast PDX include:
- Biological consistency with the tumor of origin.
- Phenotypic stability across multiple transplant generations at the histologic, transcriptomic, proteomic, and genomic levels.
- Qualitatively identical treatment responses as the tumor of origin when treated with a comparable agent
Pancreatic Cancer PDX
StemMed recently obtained exclusive license to a collection of four low passage human pancreatic cancer PDX for use in preclinical studies. We are in the process of characterizing these PDX models.